Inmagene Biopharmaceuticals: Funding, Investors & Team (Sep 2026)

Diseases do not recognize borders; why should drug innovation? We are a team of scientists and physicians driven by a shared commitment: to fulfill unmet medical needs for patients worldwide by harnessing the most effective resources and efficient processes for drug development. We may take the brainchild of a scientist in one country to conduct proof of concept studies in another, and seamlessly transition to later clinical development globally. We coined our approach “Borderless Innovation.” Focused on immunology and inflammation, we are developing a new generation of drug candidates characterized by prolonged pharmacokinetic and pharmacodynamic effects as well as improved safety margins. This will potentially enable improved efficacy/safety profiles and dosing convenience. Leveraging cutting-edge technology, we have a rich pipeline consisting of four clinical-stage assets, targeting validated pathways, and multiple innovative preclinical candidates.

Inmagene Biopharmaceuticals has raised $75.0M across 1 round on record. The most recent is an undisclosed round of $75.0M announced in Jul 2025.

Inmagene Biopharmaceuticals' most recent funding round on record is an undisclosed round of $75.0M, announced in Jul 2025.

FundedIQ lists Jonathan Wang (Founder) at Inmagene Biopharmaceuticals.

Inmagene Biopharmaceuticals is based in San Diego, California, United States.

Inmagene Biopharmaceuticals is in the 11-50 employee band.

Inmagene Biopharmaceuticals' latest round of $75.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.